Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Anebulo Pharmaceuticals, Inc. (ANEB : NSDQ)

• Company Description    Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $1.68 Daily Weekly Monthly 20 Day Moving Average: 16,765 shares Shares Outstanding: 41.08 (millions) Market Capitalization: $69.02 (millions) Beta: -0.98 52 Week High: $3.08 52 Week Low: $0.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 49.07% 41.00% 12 Week 75.00% 46.82% Year To Date 0.00% -6.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1017 Ranch Road 620 South SUITE 107 - LAKEWAY,TX 78734 USA ph: 512-598-0931 fax: - ir@anebulo.com http://www.anebulo.com

• General Corporate Information    Officers Richard Anthony Cunningham - Chief Executive Officer Joseph F. Lawler - Chairman of the Board of Directors Daniel George - Chief Financial Officer Aron R. English - Director Jason Aryeh - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 034569103 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/24/25 Share - Related Items Shares Outstanding: 41.08 Most Recent Split Date: (:1) Beta: -0.98 Market Capitalization: $69.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/24/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.13 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 55.56% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -90.11 12/31/24 - -119.54 ROA 06/30/25 - - 03/31/25 - -84.53 12/31/24 - -108.08 Current Ratio 06/30/25 - - 03/31/25 - 25.29 12/31/24 - 17.51 Quick Ratio 06/30/25 - - 03/31/25 - 25.29 12/31/24 - 17.51 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.33 12/31/24 - 0.36 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©